Radiation therapy and concomitant paclitaxel/carboplatin chemotherapy for muscle invasive transitional cell carcinoma of the bladder: A well-tolerated combination

International Journal of Cancer

Volumn 90, Issue 5, 2000, Pages 281-286

  Nichols Jr , R Charles ^a   Sweetser, Matthew G ^a   Mahmood, Syed K ^b   Malamud, Fernando C ^a   Dunn, Neal P ^c   Adams, John P ^d   Kyker, James S ^d   Lydick, Kimberly ^a  

^a Gulf Coast Cancer Treatment Center   (United States)

^b Division of Plastic Surgery   (United States)

^c Panama City Urological Center   (United States)

^d NONE

Author keywords

Bladder neoplasms; Carboplatin; Paclitaxel; Radiotherapy

Indexed keywords

CARBOPLATIN; PACLITAXEL;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLADDER CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER INVASION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE CONTROL; DOSE RESPONSE; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN TISSUE; MALE; MORBIDITY; PRIORITY JOURNAL; RADIATION DOSE; TRANSITIONAL CELL CARCINOMA; TRANSURETHRAL RESECTION; TREATMENT OUTCOME; TREATMENT PLANNING; URINARY DYSFUNCTION;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; CARBOPLATIN; CARCINOMA, TRANSITIONAL CELL; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MUSCLE NEOPLASMS; PACLITAXEL; RADIATION-SENSITIZING AGENTS; TIME FACTORS; URINARY BLADDER NEOPLASMS;

EID: 0033754310     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0215(20001020)90:5<281::AID-IJC5>3.0.CO;2-U     Document Type: Article

References (17)

1. Selective bladder preservation by combination treatment of invasive bladder cancer
2. Combined radiation and chemotherapy for invasive transitional-cell carcinoma of the bladder: A prospective study
3. Organ-sparing treatment of advanced bladder cancer: A 10-year experience
4. Combined modality program with possible organ preservation for invasive bladder carcinoma: Results of RTOG protocol 85-12
5. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: Initial results of Radiation Therapy Group 89-03
6. A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer
7. Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: A phase II trial of the Eastern Cooperative Oncology Group
8. Paclitaxel and carboplatin in patients with metastatic urothelial cancer: Results of a phase II trial
9. Paclitaxel in advanced urothelial carcinoma its role in patients with renal insufficiency and as salvage therapy
10. Paclitaxel-based second line therapy for patients with advanced chemotherapy-resistant bladder carcinoma (M1): A clinical phase II study
11. Paclitaxel, cisplatin and methotrexate combination chemotherapy is active in the treatment of refractory urothelial malignancies
12. Concurrent paclitaxel and/radiation therapy in the treatment of solid tumors
13. Taxanes in combined-modality therapy for solid tumors
14. Efficacy of radiochemotherapy with platin derivatives compared to radiotherapy alone in organ-sparing treatment of bladder cancer
15. The results of a series of 963 patients with transitional cell carcinoma of the urinary bladder primarily treated by radical megavoltage x-ray therapy
16. T3 Bladder cancer - The case for salvage cystectomy
17. Bladder cancer: Long-term follow-up results of patients treated with radical radiation